Analytical Data
-
Gene name
Lacritin
- Application
-
Alternative Names
Extracellular Glycoprotein Lacritin; LACRT
-
Species
Human
-
Source
E. coli
-
Tag
N-6*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9GZZ8
-
Expression Region
A19-A138
-
Protein Length
Partial
-
Molecular Weight
23.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Lacritin is a naturally occurring protein secreted by lacrimal glands, primarily involved in maintaining tear film stability and promoting ocular health. Research into Lacritin has gained significant traction due to its potential therapeutic applications in treating dry eye disease (DED) and other related ocular surface disorders. Dry eye disease is a prevalent condition that affects millions of people globally, leading to discomfort and visual impairment. Traditional treatments may provide temporary relief but often overlook underlying dysfunctions in tear production and composition. Lacritin has been shown to enhance tear secretion, stimulate epithelial cell proliferation, and promote the survival of corneal cells, which are crucial for ocular surface integrity. Moreover, its anti-inflammatory properties present a promising avenue for addressing the inflammatory component of DED. Studies investigating the recombinant form of Lacritin aim to comprehend its molecular mechanisms, explore its biopharmaceutical potential, and establish effective delivery methods for clinical use. By elucidating the role of Lacritin in tear film dynamics and ocular surface homeostasis, researchers hope to develop novel, targeted therapies that can significantly improve quality of life for individuals suffering from dry eye symptoms. Further studies are necessary to determine optimized dosages, evaluate long-term efficacy, and ensure safety profiles for Lacritin-based interventions in clinical settings.
